Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.70 |
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541021 | 0.98 | DGKA (0.67) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL7695250 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL8092345 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL2523641 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL2532102 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL2532357 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL2533166 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL7688943 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL2529725 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 | |
| SCHEMBL7689665 | 0.94 | DGKA (0.74) | DGKANAAAHTR2CPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957214-B2 | Multifunctional radical quenchers | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-01 | — | — | US | claimed |
| US-20150274628-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-10-01 | — | — | US | claimed |
| EP-2906207-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS | Arizona Board of Regents on behalf of Arizona State University (US) | 2015-08-19 | — | — | EP | claimed |
| WO-2014059158-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AN ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2014-04-17 | — | — | WO | claimed |
| US-9957214-B2 | Multifunctional radical quenchers | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-01 | — | — | US | disclosed |
| US-20150274628-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-10-01 | — | — | US | disclosed |
| US-8044070-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | MSD K.K. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-7595316-B2 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | MSD K.K. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1642898-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-0985671-B1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-RE34722-E | Antiulcer agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| US-4578381-A | ANTIULCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274628-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS | SQOR, UQCRC1, PRDX5 | DGKA 4778/4885NAAA 3927/4885HTR2C 3388/4885 |
| US-20060178375-A1 | Heteroaryloxy nitrogenous saturated heterocyclic derivative | HRH3, HRH4, HCRTR2 | DGKA 1940/4885NAAA 508/4885HTR2C 35/4885 |
| US-20100210637-A1 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | HRH3, HRH4, HRH2 | DGKA 2153/4885NAAA 452/4885HTR2C 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.